1型自身免疫性胰腺炎新型生物标志物的相关研究进展  

Research progress of novel biomarkers in type 1 autoimmune pancreatitis

作　　者：席文丰 李柯[1] 丁士刚[1] Xi Wenfeng;Li Ke;Ding Shigang(Department of Gastroenterology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院消化科,北京100191

出　　处：《中国医药》2023年第4期611-615,共5页China Medicine

基　　金：国家自然科学基金(82270592)。

摘　　要：自身免疫性胰腺炎(AIP)是胰腺的慢性自身免疫性疾病,较为罕见,包括1型、2型和非特指型。1型亚洲多见,2型西方国家多见。胰腺为免疫球蛋白G4(IgG4)相关性疾病最常累及的器官,血IgG4水平升高、胰腺外器官受累为1型AIP的突出表现。虽然IgG4为1型AIP的经典血清学标志物,但有其局限性,新型生物标志物或可弥补其不足。本文旨在介绍1型AIP的新型生物标志物,它们对于该病分子层面的机制解释以及诊断、病情严重程度评估等方面有重要意义,将来可能被广泛地应用于临床实践。Autoimmune pancreatitis(AIP)is a chronic autoimmune disease of the pancreas,which is relatively rare,including type 1,type 2 and not otherwise specified.Type 1 is common in Asia and type 2 is common in western countries.Pancreas is the most frequently involved organ in immunoglobulin G4(IgG4)-related disease.Elevated blood IgG4 level and extrapancreatic organ involvement are the prominent manifestations of type 1 AIP.Although IgG4 is the classical serological marker of type 1 AIP,it has its limitations.Novel biomarkers may make up for the shortcomings.This article aims to introduce the novel biomarkers of type 1 AIP,which are of great significance for mechanism explanation in the molecular level,diagnosis,and severity evaluation of the disease,and they may be widely used in clinical practice in the future.

关 键 词：自身免疫性胰腺炎 免疫球蛋白G4相关性疾病 生物标志物 

分 类 号：R576[医药卫生—消化系统]